Theravance Biopharma, Inc. Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net
Theravance Biopharma, Inc. (TBPH) reported Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net of $21.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2019-02-28.
Discontinued › Notes › Compensation Related Costs
us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet · last filed 2019-02-28
- Theravance Biopharma, Inc. adjustment to additional paid in capital, income tax effect from share-based compensation, net for fiscal 2016 was $21.00K.
- Theravance Biopharma, Inc. adjustment to additional paid in capital, income tax effect from share-based compensation, net for fiscal 2015 was -$75.00K, a 126.60% decline from fiscal 2014.
- Theravance Biopharma, Inc. adjustment to additional paid in capital, income tax effect from share-based compensation, net for fiscal 2014 was $282.00K.
| Period end | Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 12 month |
|---|---|
| 2016-12-31 | $21.00K 10-K · filed 2019-02-28 |
| 2015-12-31 | -$75.00K 10-K · filed 2018-02-28 |
| 2014-12-31 | $282.00K 10-K · filed 2017-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |